Ventyx Biosciences Inc (VTYX NASDAQ) stock market data APIs
$1.86
0.02(1.1%)
as of February 4, 2025
Ventyx Biosciences Inc Financial Data Overview
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company's lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn's disease. It is also developing VTX002, a sphingosine 1 phosphate receptor modulator that is in Phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 inflammasome inhibitor to treat patients with cryopyrin-associated periodic syndrome. In addition, the company develops VTX3232, a CNS-penetrant NLRP3 inhibitor. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in San Diego, California.
Prev. Close
1.84
Open
1.86
High
1.715
Low
2.04
52 wk Range
1.67-11.48
Market Cap
130 M
Shares Outstanding
70 711 K
Revenue
0
EPS
-0.5
Beta
0.366
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Ventyx Biosciences Inc data using free add-ons & libraries
Get Ventyx Biosciences Inc Fundamental Data
Ventyx Biosciences Inc Fundamental data includes:
- Net Revenue: 0
- EBITDA: -166 116 992
- Earnings Per Share: -2
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2024-11-04
- EPS/Forecast: -0.52
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ventyx Biosciences Inc News
New
Ventyx Biosciences to Participate in the 35th Annual Piper Sandler Healthcare Conference
SAN DIEGO, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address...
Ventyx Biosciences to Participate in the Jefferies London Healthcare Conference
SAN DIEGO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address...
Ventyx Biosciences Reports Third Quarter 2023 Financial Results and Highlights Recent Corporate Progress
Ventyx to provide updates across clinical-stage portfolio in the first quarter of 2024 Cash, cash equivalents and marketable securities of $300.8 million as of September 30, 2023 SAN DIEGO, Nov. 09...
Ventyx Biosciences Announces Results from the Phase 2 Trial of VTX958 in Patients with Moderate to Severe Plaque Psoriasis and Provides Corporate Update
VTX958 225 mg BID and 300 mg BID doses achieved statistical significance on the primary endpoint (PASI 75) and all key secondary endpoints at Week 16 Efficacy results did not meet the internal target...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
